_256_384.jpg)
News | November 04, 2025
Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr
The transaction is expected to be completed within one month from the signing of the definitive agreements.
The transaction is expected to be completed within one month from the signing of the definitive agreements.
_256_384.jpg)
Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Subscribe To Our Newsletter & Stay Updated
